Overview

Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients

Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin. One of the local treatment available is intralesional (IL) Pentostam injection. During the current study the investigators will monitor the adverse effects of this treatment and will follow up the recovery of the lesions after Pentostam injections.
Details
Lead Sponsor:
Sheba Medical Center
Treatments:
Antimony Sodium Gluconate